CLEVELAND--(BUSINESS WIRE)--Indago, a medical device and technology company, announces that Leah Brownlee, J.D., has been appointed as President and General Counsel. Ms. Brownlee, an experienced life science executive, most recently served in the Corporate Practice and Life Sciences Industry groups at Squire Patton Boggs and previously served as Executive Vice President of Compliance and Operations at Cleveland BioLabs, Inc., a clinical-stage NASDAQ-listed biotechnology company (CBLI).
Ms. Brownlee has served life science companies that range from startups to industry leaders across the pharmaceutical and medical device industries over the last 15 years.
“We couldn’t be happier to have Leah join the management team as Indago proceeds through the final stages of product development, regulatory approval, and commercial launch for its ArthroFree™ wireless arthroscopic camera system,” said Mark Froimson, M.D., Chairman of the Board.
“Leah’s vast experience in the life sciences sector, along with her leadership roles across public and private companies, makes her the ideal person to join Indago as we approach the marketing approval and launch of the ArthroFree™ system,” said Eugene Malinskiy, Chief Executive Officer.
“I am excited to be joining the Indago team as the company approaches critical milestones on the path to launching its first product,” Ms. Brownlee said. “I look forward to working alongside Eugene and the Indago team, leveraging my industry experience to help guide Indago as it grows.”
Indago is a pre-revenue medical device startup company backed by private capital. Founded in 2015, Indago has developed novel technology that will enable it to create the operating room of the future with a smart platform for a highly efficient, tech-enabled surgical suite. The company’s ArthroFree™ wireless arthroscopic camera system is a breakthrough medical device that leverages the company’s patented next generation solid-state lighting technology to create a completely wireless arthroscopic camera system designed for the operating room. The first system of its kind, ArthroFree™ is positioned to disrupt the standard of care in arthroscopy today. The company plans to submit the ArthroFree™ camera system to the FDA for marketing approval in the first half of 2021. For more information, see: www.indago.io
Forward Looking Statements
This press release includes "forward-looking statements." Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will," and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our regulatory submission timeline for ArthroFree™. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.